Considering this, inhibiting the IL-4 pathway with dupilumab might disrupt this balance contributing to the resolution of mass lesions in IgG4-RD by reducing the supply of IgG4-positive cells. This evidence concerns the gene IL4 and immunoglobulin G4-related sclerosing disease.